Drug Profile
Sovateltide - Midwestern University/Pharmazz
Alternative Names: IRL-1620; PMZ-1620; Sovatelitide; SPI-1620; Tycamzzi; TyvalziLatest Information Update: 09 Oct 2023
Price :
$50
*
At a glance
- Originator University of Illinois at Chicago
- Developer Pharmazz; Spectrum Pharmaceuticals
- Class Antidementias; Antineoplastics; Imaging agents; Neuroprotectants; Peptides; Vascular disorder therapies
- Mechanism of Action Angiogenesis modulating agents; Antioxidants; Apoptosis inhibitors; Diagnostic imaging enhancers; Endothelin B receptor agonists; Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Stroke
- Phase III Solid tumours
- Phase II Alzheimer's disease; Brain hypoxia-ischaemia; Spinal cord injuries
- Discontinued Biliary cancer; Cerebrovascular disorders; Neurodegenerative disorders; Non-small cell lung cancer